Avalo Therapeutics, Inc. appointed Ron Philip to its Board of Directors, effective June 23, 2026. Mr. Philip will serve on the Compensation Committee and the Science, Development and Commercial Advisory Committee until the 2027 Annual Meeting of Stockholders. As part of his appointment, he will receive a non-qualified stock option to purchase 40,200 shares of common stock, vesting in three equal annual installments. Mr. Philip previously held leadership roles at Spark Therapeutics, Orbital Therapeutics, and Pfizer. Avalo Therapeutics, Inc. is a biotechnology company.

Avalo Therapeutics, Inc. announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody. The therapeutic candidate is being developed for the treatment of hidradenitis suppurativa and other inflammatory disorders. The company also released an updated investor presentation on its website. Avalo Therapeutics is a biotechnology company focused on developing therapies for inflammatory diseases.

Avalo Therapeutics, Inc. entered into an exchange agreement on June 11, 2026, to exchange 4,294.675 shares of Series C non-voting convertible preferred stock for an equivalent number of newly created Series C-1 non-voting convertible preferred stock. This exchange allows an investor to increase their beneficial ownership limit from 4.99% to 9.99% of the Company's common stock. Additionally, the Company amended employment agreements for CEO Garry A. Neil, CFO Christopher Sullivan, M.D., CMO Mittie Doyle, and CBO Taylor Boyd to modify severance and change in control benefits. Avalo Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.

Avalo Therapeutics, Inc. held its 2026 annual meeting of stockholders, where stockholders approved the Second Amended and Restated 2016 Employee Stock Purchase Plan (A&R 2016 ESPP) and elected seven board nominees. Additionally, stockholders also ratified the following: Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year 2026.